Controversies in altitude medicine

Area of Science:

• Altitude Medicine
• Physiology

Background:

• Acute mountain sickness (AMS) is a common condition at high altitudes.
• Acetazolamide is a common pharmacological intervention for AMS.
• Cerebral blood flow (CBF) is hypothesized to play a role in AMS pathophysiology.

Purpose of the Study:

• To review controversies in altitude medicine regarding AMS prevention and etiology.
• To evaluate the efficacy of acetazolamide dosage for AMS prevention.
• To assess the current understanding of the relationship between CBF and AMS.

Main Methods:

• Literature review of existing studies on acetazolamide and AMS.
• Analysis of methodological limitations in studies investigating CBF and AMS.
• Discussion of experimental settings and technical tools used in CBF research.

Main Results:

• Full AMS prevention may necessitate 500-750mg of acetazolamide daily; lower doses might attenuate symptoms.
• Significant methodological issues exist in studies examining CBF and AMS.
• Current research cannot definitively establish CBF changes as an etiological factor for AMS.

Conclusions:

• Optimal acetazolamide dosage for AMS prevention requires further investigation.
• Methodological improvements are crucial for understanding the role of CBF in AMS.
• The etiological link between CBF and AMS remains to be elucidated.